Sangamo stock climbs 12% post-market on FDA update for ST-503

seekingalpha11-20

Iryna Drozd Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484890908?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","is_english":true,"pubTime":"2024-11-20 05:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2484890908","market":"us","top_or_hot":-1,"title":"Sangamo stock climbs 12% post-market on FDA update for ST-503","media":"seekingalpha","content":"<div>\n<p>Iryna Drozd Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-...</p>\n\n<a href=\"https://seekingalpha.com/news/4309358-sangamo-stock-climbs-post-market-on-fda-update-for-st-503\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo stock climbs 12% post-market on FDA update for ST-503</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo stock climbs 12% post-market on FDA update for ST-503\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 05:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4309358-sangamo-stock-climbs-post-market-on-fda-update-for-st-503><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iryna Drozd Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-...</p>\n\n<a href=\"https://seekingalpha.com/news/4309358-sangamo-stock-climbs-post-market-on-fda-update-for-st-503\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://seekingalpha.com/news/4309358-sangamo-stock-climbs-post-market-on-fda-update-for-st-503","article_id":"2484890908","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484890908","pubTimestamp":1732053102,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Iryna Drozd Shares of Sangamo Therapeutics  rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-503 in the treatment of intractable pain due to idiopathic small fiber neuropathy, or iSFN. The company plans to begin enrolling patients in a Phase 1/2 study for ST-503 for the indication in mid-2025, according to a statement. Sangamo  said if the study is successful, development of ST-503 could be broadened to other types of chronic neuropathic pain.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","SGMO":"Sangamo Therapeutics Inc","BK4139":"生物科技"},"translate_title":"FDA更新ST-503后，Sangamo股价盘后上涨12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMO":0.9},"content_text":"Iryna Drozd Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-503 in the treatment of intractable pain due to idiopathic small fiber neuropathy, or iSFN. The company plans to begin enrolling patients in a Phase 1/2 study for ST-503 for the indication in mid-2025, according to a statement. Sangamo (SGMO) said if the study is successful, development of ST-503 could be broadened to other types of chronic neuropathic pain.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484890908"}